Eleven-year temporal trends of clinical characteristics and long-term outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndrome in the Shinken database.
Acute coronary syndrome
Percutaneous coronary intervention
Time trend
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
30
03
2018
accepted:
20
07
2018
pubmed:
26
7
2018
medline:
12
3
2019
entrez:
26
7
2018
Statut:
ppublish
Résumé
Despite the increasing incidence of acute coronary syndrome (ACS) in Japan, its prognosis has improved. However, there is a paucity of longitudinal registry data providing trends of in-hospital care and prognosis of ACS in Japan. ACS patients undergoing percutaneous coronary intervention (PCI) included in the Shinken Database 2004-2014 were divided into two groups according to admission year (2004-2009, n = 390; 2010-2014, n = 328). Patient characteristics, lesion/procedure characteristics, medications at discharge, all-cause mortality, cardiovascular death, acute myocardial infarction (AMI), target lesion revascularization (TLR), re-PCI to new lesion, and coronary artery bypass graft (CABG) within 2 years after discharge were compared between the groups. Prevalence of hypertension, dyslipidemia, and dual antiplatelet/statin prescription increased significantly between periods. Usage of second-generation drug-eluting stents (DES) increased markedly between the two periods (2.6, 66.8%), while those of bare metal stents (64.4, 26.5%) and first-generation DES (25.6, 1.5%) decreased (all, p < 0.01). Two-year event-free survival rate increased for all-cause mortality (94.6-98.3%, p = 0.01), TLR (79.4-96.1%, p < 0.01), and re-PCI to new lesion (87.3-95.1%, p < 0.01). There were no significant differences in cardiovascular death, AMI, or CABG between the two periods. The event-free rates for TLR and re-PCI to new lesion in ACS patients have increased over the last decade in Japan. These observations should be confirmed in larger, longitudinal, multicenter registries.
Identifiants
pubmed: 30043155
doi: 10.1007/s00380-018-1229-y
pii: 10.1007/s00380-018-1229-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-207Références
Circulation. 2001 Jul 3;104(1):19-24
pubmed: 11435332
Eur Heart J. 2005 Apr;26(8):804-47
pubmed: 15769784
Circulation. 2004 Feb 17;109(6):745-9
pubmed: 14970110
Circ J. 2008 Jun;72(6):914-20
pubmed: 18503216
Am J Cardiol. 2004 May 15;93(10):1218-22
pubmed: 15135692
Circulation. 2004 Aug 3;110(5):522-7
pubmed: 15262842
J Cardiol. 2011 Sep;58(2):116-23
pubmed: 21820280
Am Heart J. 2007 Dec;154(6):1108-15
pubmed: 18035083
Arch Cardiovasc Dis. 2010 Jun-Jul;103(6-7):363-75
pubmed: 20800800
Am Heart J. 2009 Mar;157(3):509-516.e1
pubmed: 19249422
J Cardiol. 2015 Oct;66(4):326-32
pubmed: 25578787
Am J Cardiol. 2004 Jul 1;94(1):25-9
pubmed: 15219503
Curr Med Chem Cardiovasc Hematol Agents. 2005 Jul;3(3):195-201
pubmed: 15974884
Circulation. 1998 Jun 23;97(24):2433-44
pubmed: 9641696
Circ J. 2017 Mar 24;81(4):520-528
pubmed: 28154296
Circulation. 2002 Sep 10;106(11):1390-6
pubmed: 12221058
J Am Coll Cardiol. 2008 Jul 1;52(1):71-9
pubmed: 18582638
J Am Coll Cardiol. 2013 Jun 11;61(23):e179-347
pubmed: 23639841
Eur Heart J. 2002 Feb;23(3):230-8
pubmed: 11792138
Lancet. 2002 Sep 7;360(9335):743-51
pubmed: 12241831
J Am Coll Cardiol. 2008 Nov 25;52(22):1769-81
pubmed: 19022156
Circ J. 2013;77(4):934-43
pubmed: 23502993
Circ J. 2010 Jan;74(1):93-100
pubmed: 19942783
Lancet. 1999 Aug 28;354(9180):708-15
pubmed: 10475181